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Scopolamine effects on 
functional brain connectivity: 
a pharmacological model of 
Alzheimer’s disease
R. Bajo1*, S. Pusil1*, M. E. López1, L. Canuet1, E. Pereda2, D. Osipova3, F. Maestú1 & 
E. Pekkonen3, 4
Scopolamine administration may be considered as a psychopharmacological model of Alzheimer’s 
disease (AD). Here, we studied a group of healthy elderly under scopolamine to test whether it 
elicits similar changes in brain connectivity as those observed in AD, thereby verifying a possible 
model of AD impairment. We did it by testing healthy elderly subjects in two experimental 
conditions: glycopyrrolate (placebo) and scopolamine administration. We then analyzed 
magnetoencephalographic (MEG) data corresponding to both conditions in resting-state with eyes 
closed. This analysis was performed in source space by combining a nonlinear frequency band-specific 
measure of functional connectivity (phase locking value, PLV) with network analysis methods. 
Under scopolamine, functional connectivity between several brain areas was significantly reduced 
as compared to placebo, in most frequency bands analyzed. Besides, regarding the two complex 
network indices studied (clustering and shortest path length), clustering significantly decreased 
in the alpha band while shortest path length significantly increased also in alpha band both after 
scopolamine administration. Overall our findings indicate that both PLV and graph analysis are 
suitable tools to measure brain connectivity changes induced by scopolamine, which causes 
alterations in brain connectivity apparently similar to those reported in AD.
Functional Connectivity (FC) has been proposed1–3 as an approach to describe how brain regions coor-
dinate to support higher cognitive functions. FC measures the statistical interdependencies between 
two time series (brain signals) and is related to the ability to communicate information between brain 
regions which underlies many cognitive functions. Since FC provides information on the relationship 
between simultaneously recorded signals4, it has been extensively used to gain insight into the interac-
tions between the corresponding brain regions. Subsequently, with the aim to describe the functional 
brain network associated to a FC pattern, different graph theoretic methods have been used3,5–7. Graph 
theory allows representing a complex set of relationships (i.e. a network) as an ensemble of nodes inter-
connected by links. Here, the nodes are the MEG sensors with their corresponding electrophysiological 
information, and the links between two MEG sensors are the corresponding estimation of the strength 
of FC, in our case, the Phase Locking Value (PLV), as detailed below.
Scopolamine, a muscarinic receptor antagonist, produces a blocking of the activity of the muscarinic 
acetylcholine receptor, and the concomitant appearance of transient cognitive amnesia and electrophysi-
ological changes, which resemble those observed in Alzheimer’s Disease (AD)8,9. Indeed, to date, several 
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studies have explored neurophysiological changes associated with scopolamine injection mirroring those 
observed in AD10. After scopolamine administration, quantitative electroencephalogram resting state 
studies have found decreased power in alpha and beta bands, and increased delta and theta activity11–14. 
Additionally, studies using coherence during resting-state have shown a decrease in this measure after 
scopolamine12,15. Further, an interesting recent study on reconstructed EEG sources using LORETA9, 
found changes in brain activity following scopolamine administration, mainly at the precuneus. Taken 
together, these neurophysiological and cognitive alterations suggest that the administration of scopola-
mine may be an adequate approximation to simulate the modifications in brain activity that take place 
in AD13.
Regarding the application of FC to electrophysiological data in the study of AD, several studies have 
showed an increase in slow band (i.e. delta band) connectivity in AD and a reduction in FC among 
different cortical areas (e.g. fronto-parietal, fronto-temporal and parieto-occipital circuits) in alpha and 
beta bands5,16–18. Additionally, Osipova et al.12 studied the effect of scopolamine administration on MEG 
spectral power and coherence. They measured spectral power and coherence over 7 brain regions (fron-
tal, central, left temporal, right temporal, left parietal, right parietal, and occipital) in 3 frequency bands 
(theta: 4-8 Hz, alpha: 8-13 Hz and beta: 13-22 Hz). In this work, however, coherence was computed in 
the sensor space between only 8 MEG channels, which limited the implication of the results. Instead, we 
re-analyzed here the whole data set (using all MEG channels available: 122) by combining graph theory 
with a nonlinear index of phase synchronization, the PLV, to study FC in the source space, between 88 
brain regions, in 5 frequency bands. To the best of our knowledge, no research hitherto has evaluated the 
effects of scopolamine on the network MEG structure at the source domain. We hypothesize that func-
tional MEG connectivity in source space will decrease after scopolamine administration as compared to 
placebo, and also that the architecture of the functional brain network, assessed by graph theory analysis, 
will resemble that observed in AD´s patients. Besides, the current study will also provide evidences of a 
model of AD and of the usefulness of FC analysis in the study and description of brain networks.
Materials and Methods
The subjects of the present study are a subset of those from Osipova et al.12, who were carefully selected 
according to the quality of the recordings. They consisted of 7 healthy right-handed elderly volunteers 
(59-80 years and 6 females), recruited from a community cultural center for elderly citizens. Scopolamine 
hydrobromide (0.3 mg) or glycopyrrolate (0.2 mg), which acted as placebo without penetrating the 
blood-brain barrier, was given intravenously to each subject in a double blind, cross-over design. The 
subjects were instructed to move as little as possible and remain awake, while keeping their eyes closed. 
Magnetic fields were then recorded during this resting state using a 122-channel whole-head MEG device 
(Neuromag Ltd, Finland) confined in a magnetically shielded room. Raw data were sampled at 400 Hz 
and band-pass filtered between 0.03–150 Hz. Time-segments containing artifacts (e.g. amplitudes over 
3 pT/cm), were considered extra-cerebral noise. Analyses were performed for the commonly used fre-
quency bands, in order to facilitate comparison with other studies: delta (0.5–4 Hz), theta (4–8 Hz), alpha 
(8–12 Hz), beta (13–30 Hz) and gamma (30–45 Hz).
To reconstruct the neural MEG sources, we selected 88 brain regions derived from a BrainVisa atlas19, 
using Brainstorm software20 to define anatomical regions of interest. This number of regions was enough 
to describe the functional brain network, considering the available 122 MEG channels. Besides an expert 
neurologist certified its suitability from the point of view of brain functionality. Because brain MRIs of 
the subjects were not available, we calculated source activity by using the default anatomy in this toolbox, 
which consisted of the segmented cortical surface (15000 vertices) of the MNI/Colin27 brain21. We chose 
overlapping sphere method (OS) with Brainstorm default parameter settings to solve the forward prob-
lem. This approach in combination with minimum-norm method (MNM) provides the better outcome 
when the MRIs are not available22. Next, a noise covariance matrix was calculated to estimate noise level 
in the MEG recordings. Then, weighted minimum-norm estimation wMNE23 was chosen to compute 
source activity. The grid of sources (dipoles) was defined by the cortex surface template of the default 
anatomy; each vertex of this surface was considered as a dipole. Finally, we extracted the time series from 
these cortical ROIs as the average of all dipole’s signals within each area of the atlas mentioned above.
The abovementioned PLV was used to measure functional connectivity between all 88 brain regions, 
in each frequency band. First, data were band-pass filtered using a zero-phase distortion finite impulse 
response filter with a bandwidth of 2 Hz. Then, we obtain the complex analytic signal from each of the 
brain regions by using the Hilbert transform (see, e.g.,4 for details). Subsequently, the PLV between the 













where N is the length of the time series (in our case, N=96000, which equals 120s.) and ϕx(k) (resp. 
ϕy(k)) is the phase of x(k) (resp. y(k)). Finally, the PLV in each of the frequency bands (delta, theta…) 
was obtained by averaging the corresponding PLVs in the given frequency range.
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Additionally, we described the architecture of the functional brain network of the subjects by means 
of two indices: the clustering coefficient (C) and the average shortest path length (L). The former one 
is a measure of graph segregation that indicates how the neighborhoods of a node are interconnected. 
The latter one is an estimation of network integration, which measures the average of all the shortest 
distances between pairs of nodes in the network25–27. We calculated the mentioned network parameters 
(C and L) from the weighted matrix (PLV values) using the “Brain Connectivity Toolbox”25 (http://www.
brain-connectivity-toolbox.net). The size of the graph was 88 nodes (corresponding with the 88 source 
space regions described). Indices are un-normalized.
Statistical differences between experimental conditions (scopolamine vs. placebo), were investigated 
for both C and L by means of a paired t-test at the p<0.05 level. In the case of the PLV, we first applied 
a Kruskal-Wallis test and further a non-parametric permutation test with 1000 permutations to each of 
the significantly different PLVs to correct for multiple comparisons across the full range of functional 
connectivity pairings. In this latter case, we set the level of significance at p<0.005.
Ethics statement: Methods were carried out in “accordance” with the approved guidelines. The study 
was approved by the National Agency for Medicine of Finland and the Ethics Committee of the local 
University Hospital (Helsinki University Central Hospital, Helsinki). Besides, a written informed consent 
was obtained from all the subjects after a detailed explanation of the procedures.
Results
Scopolamine significantly increased connectivity in the delta band and significantly reduced it in the 
alpha, beta and gamma band as compared to glycopyrrolate (placebo). Fig. 1 shows the distribution of 
these changes across different cortical regions. Particularly, in the delta band scopolamine increased con-
nectivity between the left parahippocampal and the right inferior occipital cortex. Additionally, we found 
reduced connectivity in the alpha band between the left superior frontal and the left angular cortex, the 
left superior temporal pole and the right precentral cortex, and between the right angular and the left 
lingual cortex. In the beta band, we found significantly reduced connectivity, specifically between the 
left medial superior frontal and the left superior parietal cortex, the left precuneus and the right lingual 
cortex, and between the left superior parietal and right fusiform cortex. Finally, in the gamma band, 
there was significantly reduced connectivity between the right middle frontal cortex and the left rolandic 
Figure 1. Significant differences in PLV between the Glycopyrrolate (placebo) and the scopolamine 
conditions for different frequency bands (at the p<0.005 level). In the delta band (top left) the 
synchronization between left parahippocampal and right occipital interior cortex increases under the 
scopolamine. On the contrary in alpha (top right), beta (bottom left) and gamma bands (bottom right) the 
PLV decreases between different brain regions under scopolamine.
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operculum, and between the right middle orbito-frontal cortex and the right precuneus. We also found 
reduced gamma band connectivity of the left inferior frontal operculum with the right lingual and left 
paracentral lobule.
As for the brain network indices, C shows a significant reduction (p<0.04) and L a significant increased 
(p<0.04) both of them under scopolamine as compared to placebo in the alpha band, as depicted in 
Fig. 2.
Discussion
We have investigated here whether functional brain networks were impaired after the administration 
of a cholinergic receptor antagonist (scopolamine) in healthy elderly subjects. Additionally we evalu-
ated whether the effects of scopolamine on FC and functional MEG network structure mirrored the 
disconnection syndrome reported in AD patients5,28,29. Our findings showed that, compared to placebo, 
scopolamine significantly increases MEG phase synchronization in the delta band, specifically between 
the left medial temporal region (i.e. para-hippocampus) and the contralateral occipital cortex (taking into 
account the reservations, in terms of precision, which involves the calculation of such deep sources). This 
increment in slow band connectivity may reflect the excitotoxicity or pathological effect of scopolamine 
administration and was probably the result of the cholinergic cortical deafferentation from subcortical 
structures16–18. Scopolamine, however, decreased functional connectivity between several cortical regions 
in alpha, beta and gamma bands. In the alpha band, this reduction involved the left fronto-parietal 
and the inter-hemispheric fronto-temporal and parieto-occipital connectivity. Abnormalities in faster 
frequencies were characterized by reduced inter-hemispheric connections of the left parietal cortex (i.e. 
beta band) and the frontal lobes (i.e. gamma band). Using another index of phase synchronization, the 
so-called phase lag index (PLI), Stam et al.5 reported that MEG resting-state FC was decreased in AD 
patients for frequencies above 8 Hz. In fact, and consistent with our results, these authors found lower 
left fronto-parietal connectivity values in AD relative to healthy controls for the alpha band, as well as 
a disruption in fronto-temporal and parieto-occipital circuits. There was also a significant impairment 
of right parietal lobe connections. For faster frequencies (13-30 Hz), they also observed a predominant 
decrease in interhemispheric frontal connectivity and in fronto-parietal circuits. Moreover, consistent 
with our outcomes, most studies hitherto have found decreased functional connectivity mainly in alpha 
and beta bands in AD patients compared to healthy controls10,16,30–32.
Figure 2. (a) Network parameters (C and L mean values) for each frequency band and condition (placebo 
and Scopolamine); (b) Statistically significant differences (p values) for C and L, when comparing both 
conditions (Glycopyrrolate (placebo) vs. Scopolamine) for each frequency band; (c) In alpha band, C shows 
a significant reduction under scopolamine as compared to placebo, while L shows a significant increased.
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Several cortical regions showing scopolamine-induced FC decrease in this study (e.g. precuneus, 
medial frontal and inferior parietal cortex) are part of the default mode network (DMN), which is known 
to be active during resting and attenuated during cognitive tasks. Specific regions of the DMN, includ-
ing the precuneus in the medial parietal cortex, are selectively vulnerable to early pathological changes 
in AD33. Besides, precuneus was identified as a critical anatomical area9,34,35, thus suggesting that this 
structure could be a “network hub” which is affecting other functional regions. Beyond the DMN, other 
cortical areas showed loss of FC. For instance, we also found abnormal connectivity in areas of the ante-
rior temporal network, including the hippocampus and the temporal pole36. Interestingly, this network 
is involved in memory function, which is typically impaired in AD33.
It is noteworthy that cortical areas that belong to other brain networks also exhibited disruption in 
FC after scopolamine administration. These networks include the fronto-parietal and the dorso-lateral 
prefrontal ones, which are involved in attention and executive functions, respectively. As mentioned 
above, Iturria-Medina et al.35 identified “the most indispensable and critical anatomical areas in the 
brain network”, which among others also included: superior parietals and superior frontals. These regions 
that were also disrupted by scopolamine administration are important brain network hubs. Besides, 
this finding is in line with that of a recent resting-state fMRI study37 reporting disrupted functional 
connectivity between multiple brain networks in AD. Taken together, these findings suggest that there 
is scopolamine-related disorganization of several cortical networks, where the DMN appears to be par-
ticularly compromised.
In addition to connectivity analysis in source space, we examined changes in the large-scale structure 
of resting-state functional brain networks using concepts from graph theory. In a recent review, Tijms 
et al.29 claim that the un-normalized path length (L) was most consistently reported (6 of 8 studies) to 
be increased in AD. This increase has been usually interpreted to result from the loss of connectivity. 
Moreover, regarding the clustering (C) index, these authors indicate that no definite differences have 
been found between both groups (AD and Controls), since the studies reviewed showed considerable 
variability. Hence, the present study is consistent with the findings reported the literature about the 
increase of path length in AD, and supports the idea that the clustering index decreases in the lower 
alpha band in AD patients as compared to healthy subjects5.
Thus, what we have found here supports the idea that scopolamine may be considered as a psychop-
harmacological model of AD, since both the drug and the disease produce a similar disruption in FC 
and brain network architecture. Importantly, donepezil, a drug belonging to the family of cholinesterase 
inhibitors, has been reported to improve abnormalities in FC of the hippocampus and prefrontal areas38, 
which provides further support to this argument.
Overall, the present study shows that the pharmacological induction of amnesia in a group of healthy 
elderly subjects seems to produce a similar disruption of FC and functional MEG brain networks organ-
ization to that reported in AD patients. At any rate, some reservations must be pointed out before con-
firming that scopolamine administration produces similar alterations that those observed in AD patients. 
It is necessary to indicate that in the present study we did not perform any correlations between FC and 
the behavioral data while subjects were under scopolamine condition. In addition, we did not analyze 
an AD cohort but rather discuss our findings in the context of the existing literature of AD effects on 
functional MEG connectivity5,10,18,39. From these results, and considering the limitations discussed, we 
conclude that the assessment of functional MEG connectivity and the subsequent characterization of the 
brain network structure may be a useful approach to understand AD, and provide new strong evidences 
of the usefulness of combining both methodologies to study brain function from multivariate neuroim-
aging data in health and disease.
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